Collaboration Opportunity: Novel Mouse Models of Human Hepatitis B Virus Infection for Drug Discovery and Vaccine Research

Tech ID: 22413 / UC Case 2012-026-0

Brief Description

UCSF researchers have generated and validated mouse models of hepatitis B virus (HBV) infection that recapitulate the key differences in viral clearance and persistence between early life (resulting primarily in chronic infections) and adulthood infection (often acute infections). The two transgenic mouse models – HBVRplRag and HBVEnvRag – offer a novel system for studying primary HBV infection for use in drug discovery and vaccine research.

Background

HBV infection can lead to chronic infections that result in 0.6 million deaths per year worldwide by causing liver failure and cancer. Clearance of HBV infection is age dependent, with the majority of adult-acquired infections leading to spontaneous clearance, whereas infection in young children often leads to chronic infections. To study these early events of infection and immune activation that lead to HBV clearance or persistence, in vivo models are needed to screen and validate lead drug candidates. HBV cannot infect mice, however, researchers at UCSF have generated transgenic mouse models that mimic critical features of primary HBV infection observed in humans.

Technology Description

Partnership Opportunities

The UCSF investigators have generated two HBV-transgenic mouse systems that can be used to reveal disease mechanisms involved in human HBV immunopathogenesis: HBVEnvRag - Rag1-deficient mouse expressing viral antigens (HBV small, middle and large envelope proteins) in the liver, and HBVRplRag - Rag1-deficient mouse that allows viral replication and release of infectious virions.  

Reconstitution of these novel transgenic mice with naïve B and T cells results in immune responses that occur in a natural primary HBV infection. Detailed information on the HBV mouse models can be found in the recent publication:  

Publicover J, Goodsell A, Nishimura S, Vilarinho S, Wang ZE, Avanesyan L, Spolski R, Leonard WJ, Cooper S, Baron JL. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. The Journal of Clinical Investigation. 2011 Mar 1;121(3):1154-62.  


This breakthrough work in HBV research was also highlighted in the following articles:  

  • Nature Reviews Immunology. 2011 Apr;11(4):236-7. “Antiviral immunity: IL-21 comes with age”  

  • Nature Reviews Gastroenterology Hepatology. 2011 May;8(5):243. “Viral hepatitis: Interleukin 21 has a key role in age-dependent response to HBV.”  

  • Hepatology. 2011 Oct;54(4):1477-9. “Hepatitis B virus infection: a strong case against ageism.”   


The investigators welcome the opportunity to collaborate with industry partners on projects using these mouse models to (i) develop therapeutic vaccines to treat  HBV, and (ii) identify therapeutic candidates for treating HBV infection by modulating novel targets identified by the investigators and through the discovery of additional clinically relevant targets. 

Advantages

  • Novel age-dependent HBV infection models that mimic HBV immunopathogenesis during human infection. 

  • Small animal model allows for critical preclinical studies in drug discovery and vaccine research.  

  • Clearly defined experimental outcomes for identifying and testing therapeutic candidates to prevent and treat chronic HBV. 

  • Models can be used for rational design of new therapeutic interventions.  

  • Testing of existing immune-modulatory therapeutics and vaccines in a mouse model of chronic HBV infection. 

Inventor Information

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Baron, Jody L.

Other Information

Keywords

hepatitis B virus, vaccine, drug discovery, collaboration, partnership, in vivo model, mouse model, preclinical testing

Categorized As